At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
In this study, researchers are assessing the safety and effectiveness of giving the drug disitamab vedotin alone and in combination with pembrolizumab immunotherapy in people with inoperable or metastatic urothelial cancers that make too much of the HER2 protein. Disitamab vedotin targets and kills cancer cells with the HER2 protein. Pembrolizumab boosts the power of the immune system to detect and destroy cancer cells.
- Pilot Study of Homebound Stem Cell Transplantation for Patients with Multiple Myeloma
Full Title Pilot Trial of Homebound Stem Cell Transplantation
Purpose
Autologous stem cell transplantation (ASCT) is a treatment in which some of a patient’s stem cells are removed before high-dose chemotherapy, then returned to the patient to help re-establish the patient’s immune system after chemotherapy. Care for a patient after ASCT usually takes place in a hospital. In this study, researchers want to see if it is feasible to care for a patient at home after ASCT for multiple myeloma. Studies at other institutions suggest that providing care at home after ASCT is safe, increases patient satisfaction, and can lower the risk of infection.
Patients in this study will have their stem cells re-infused in an outpatient setting in the hospital and then continue their care at home.
Who Can Join
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have multiple myeloma and plan to have ASCT.
- Patients must have adequate caregiver support and a wireless Internet connection at the home where they will be recovering after ASCT.
- This study is for people ages 18 to 80.
For more information about this study and to inquire about eligibility, please contact Dr. Heather Landau at 212-639-8808.
Protocol
15-022Phase
Pilot (small research study)Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT02671448ClinicalTrials.gov
-
The purpose of this study is to find the highest dose of the investigational treatment UCART22 that can be given safely in children and young adults with B-cell acute lymphoblastic leukemia (ALL) that has come back or continued to grow despite treatment. UCART22 is a form of CAR T-cell therapy. It is made from white blood cells (T cells) from healthy donors. The T cells are genetically modified in a laboratory to identify and destroy cancer cells containing a protein called CD22.
-
This clinical trial explores a novel approach to treating mantle cell lymphoma (MCL). Researchers are integrating targeted agents into standard induction and maintenance chemoimmunotherapy.  The people in this study have MCL that has not yet been treated.
-
Chemotherapy can cause symptoms, such as nausea and fatigue, and some patients have difficulty working during this treatment. The purpose of this study is to learn more about how chemotherapy for breast cancer affects patients' employment.
- A Phase II Study of Pembrolizumab Immunotherapy plus Chemotherapy followed by Autologous Stem Cell Transplantation for Recurrent or Persistent Hodgkin Lymphoma
Full Title Phase II Study of Second-Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Purpose
The purpose of this study is to assess the safety and effectiveness of combining pembrolizumab immunotherapy with standard chemotherapy drugs and autologous stem cell transplantation (ASCT) in patients with Hodgkin lymphoma that has come back or continued to grow despite one regimen of prior therapy. Pembrolizumab blocks PD-1, a protein cancer cells use to evade detection by the immune system, thereby enabling the immune system to find and kill cancer cells.
In this study, patients will receive pembrolizumab with three chemotherapy drugs: gemcitabine, vinorelbine, and liposomal doxorubicin. Depending on how well they respond to this treatment, they may also have ASCT. During ASCT, a patient’s own blood-forming stem cells are collected, and he or she is then treated with high doses of chemotherapy. Afterward, the collected stem cells are re-infused back into the patient to re-establish the blood-forming system.
The drugs used in this study are given intravenously (by vein).
Who Can Join
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have recurrent or persistent Hodgkin lymphoma after no more than one prior regimen of therapy.
- Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
- This study is for patients age 10 and older.
For more information and to inquire about eligibility for this study, please contact Dr. Alison Moskowitz at 212-639-4839.
Protocol
18-160Phase
Phase II (phase 2)Disease Status
Relapsed or RefractoryInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT03618550ClinicalTrials.gov
-
CAR T-cell therapy is a form of immunotherapy used to treat some adults with lymphoma. The treatment involves utilizing a patient's own T cells and genetically modifying them in the laboratory to recognize a protein on their cancer cells. The modified T cells, known as CAR T cells, are then returned to the patient to find and kill cancerous cells throughout the body.
-
Researchers want to learn if canakinumab can prevent cancer from developing in people with clonal cytopenia of undetermined significance (CCUS). In CCUS, there is a mutation (change) in one or more of the genes that help blood cells develop. People with CCUS have low levels of certain kinds of blood cells.
-
This study will compare the effects of different amounts of aerobic exercise on heart and lung (cardiorespiratory) fitness in post-menopausal women who completed treatment for early-stage breast cancer. Researchers will study the effects of different exercise programs on oxygen use, heart pumping ability, lung function, and blood vessel health. Participants will be randomly assigned to one of four groups:
- A Phase 2 Study of Belumosudil After a Stem Cell Transplant to Prevent Graft-Versus-Host Disease
Full Title Phase II Open Label Prospective Nonrandomized Trial of Belumosudil for Switch-Maintenance Prophylaxis of Graft-versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation
Purpose
After a stem cell transplant, some patients develop a condition called graft-versus-host disease (GVHD). This occurs when the donor’s healthy immune cells see the recipient’s normal cells as foreign and begin to attack them.
GVHD can affect many parts of the body, including the skin, liver, stomach, intestines, joints, eyes, mouth, and lungs. It can range from mild to severe and is a common cause of reduced quality of life after a transplant.
This study aims to find out whether giving belumosudil, in addition to standard immunosuppressive therapy, can reduce GVHD risk. Belumosudil is an oral medication that works by blocking specific proteins that control immune system activity. By keeping the immune system in balance, belumosudil may help prevent GVHD. It will be given around day 100 after the transplant
If you take part in this study, you will get belumosudil as well as the usual treatment to prevent GVHD. This treatment includes tacrolimus with or without cyclophosphamide chemotherapy. Your doctor will let you know whether or not you will get cyclophosphamide.
Who Can Join
To join this study, there are a few conditions. You must:
- Have had an allogeneic stem cell transplant (from a donor) for blood cancer and received cyclophosphamide or abatacept treatment to prevent GVHD.
- Have received your stem cell transplant no more than 4 months before entering the study.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Doris Ponce’s office at 646-608-3739.
Protocol
25-033Phase
Phase II (phase 2)Disease Status
Relapsed or RefractoryInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT07006506ClinicalTrials.gov